Interpreting the Enhance Trial

Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications

  • Cleveland Clinic Journal of Medicine
  • July 2008,
  • 75
  • (7)
  • 479-491;
This is a PDF-only article. The first page of the PDF of this article appears above.

Footnotes

  • * Dr. Davidson has disclosed that he has received consulting fees, honoraria, or grant support from Abbott Laboratories, Access Health, AstraZeneca Pharmaceuticals, Atherogenics, Daiichi-Sankyo, diaDexus, Kinemed, Merck & Co, Merck/Schering-Plough, Oscient Pharmaceuticals, Pfizer Laboratories, PreEmptive Meds, Roche Pharmaceuticals, sanofiaventis, Synarc, and Takeda Pharmaceuticals for consulting, speaking, research, or serving on advisory boards. He also owns equity in or is on the board of directors of Angiogen, Professional Evaluation Inc, Medical Education Company, and Sonogene.

Loading
  • Print
  • Download PDF
  • Article Alerts
  • Email Article
  • Citation Tools
  • Share

Jump to section